Remove 2028 Remove Drug Development Remove Pharmaceuticals Remove Research
article thumbnail

Price of non-human primates drops in China following Covid boom

Drug Discovery World

A drop in the prices of non-human primates (NHPs) in China indicates a post-pandemic slowdown in Chinese drug development, according to a report in the Financial Times. Investment in China’s healthcare sector fell from $31 billion in 2021 to $12 billion last year, according to UBS research. The figures are taken from UBS data.

Vaccine 130
article thumbnail

Can Singapore become a global hub for biotech?

Drug Discovery World

Thanks to significant investment by the government into research and development, Singapore has become a leading centre for biomedical sciences in Asia. According to Statista, revenue in this sector is expected to grow at an annual rate of 6.77%, resulting in a market volume of US$2,208m by 2028 1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Highs and lows of drug repurposing 

Drug Discovery World

It’s common knowledge that drug discovery and development is costly, lengthy and has no guarantee of success. It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. Benefits and barriers .

article thumbnail

Investment Trends in Pharmaceutical Research

DrugBank

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.    The average cost of bringing a new drug to market is about $2.6 trillion by 2028. reported in 2021.

article thumbnail

Models of Life

Codon

The lab created a plan with eight research institutions across three continents. 2028 Over the next year, the scientific community ferociously interrogated the model. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. However, no such dataset existed.

article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

In some less common cases, a test or diagnostic may be technically classified as a biological product and regulated under the Center for Biologics Evaluation and Research (CBER) (e.g., A sea change for lab tests, the implications for drug developers and outstanding questions about endpoints In the U.S., In the U.S.,

FDA 40